Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis

Arthritis and Rheumatism

Volumn 39, Issue 1, 1996, Pages 34-40

  Van Gestel, A M ^a   Prevoo, M L L ^a   Van 'T Hof, M A ^b   Van Rijswijk, M H ^c   Van De Putte, L B A ^a   Van Riel, P L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYARTHRITIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DISCRIMINANT ANALYSIS; EUROPE; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; SULFASALAZINE; TREATMENT OUTCOME; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 0030068817     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780390105     Document Type: Article

References (24)

1. Felson DT, Anderson JJ, Meenan RF: Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials. Arthritis Rheum 33:140-149, 1990
2. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, Buchanan WW: Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 37:393-406, 1968
3. Van der Heijde DMFM, van 't Hof MA, van Riel PLCM, Theunisse LAM, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LBA: Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49:916-920, 1990
4. Van Riel PLCM, van de Putte LBA: DC-ART: what proportion of response constitutes a positive response? J Rheumatol Suppl 21:54-56, 1994
5. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, Tubwell P, Weinblatt M, Williams HJ, Wolfe F, Kieszak S: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727-735, 1995
6. Furst DE: Considerations on measuring decreased inflammatory synovitis. ILAR Bull 2:17-21, 1994
7. Tugwell P, Bombardier C: A methodologic framework for developing and selecting endpoints in clinical trials. J Rheumatol 9:758-762, 1982
8. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA: 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 9:175-176, 1958
9. Van 't Hof MA, Kowalski CJ: In, A Mixed Longitudinal Interdisciplinary Study of Growth and Development. Edited by B Prahl Anderson, CH Kowalski, P Heyendaal. New York, Academic Press, 1979
10. Nuver-Zwart HH, van Riel PLCM, van de Putte LBA, Gribnau FWJ: A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis. Ann Rheum Dis 48:389-395, 1989
11. Van der Heijde DMFM, van Riel PLCM, Nuver-Zwart HH, Gribnau FWJ, van de Putte LBA: Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1:1036-1038, 1989
12. Van der Heijde DMFM, van Riel PLCM, van de Putte LBA: Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine and sulphasalazine. Scand J Rheumatol 19:407-412, 1990
13. Fries JF, Bloch DA, Sharp JT, McShane DJ, Spitz P, Bluhm GB, Forrester D, Genant H, Gofton P, Richman S, Weissman B, Wolfe F: Assessment of radiologic progression in rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 29:1-9, 1986
14. Paulus HE, Egger MJ, Ward JR, Williams HJ, and the Cooperative Systematic Studies of Rheumatic Disease Group: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 33:477-484, 1990
15. Davis MJ, Dawes PT: A disease activity index: its use in clinical trials and disease assessment in patients with rheumatoid arthritis. Semin Arthritis Rheum 23 (Suppl 1):50-56, 1993
16. Scott DL: A simple index to assess disease activity in rheumatoid arthritis. J Rheumatol 20:582-584, 1993
17. Kirwan JR: Outcome measures in rheumatoid arthritis clinical trials: assessing improvement. J Rheumatol 20:543-545, 1993
18. Dixon JS: Response criteria for slow acting antirheumatic drugs (letter). Ann Rheum Dis 49:819-820, 1990
19. Boers M: Low-dose prednisone in rheumatoid arthritis patients: placebo treatment? (Letter) Arthritis Rheum 34:501-502, 1991
20. Fuchs HA: The use of the disease activity score in the analysis of clinical trials in rheumatoid arthritis. J Rheumatol 20:1863-1866, 1993
21. Anderson JJ: Sensitivity to change of rheumatoid arthritis clinical trial outcome measures. J Rheumatol 20:535-537, 1993
22. Dixon JS, Hayes S, Constable PDL, Bird HA: What are the "best" measurements for monitoring patients during short-term second-line therapy? Br J Rheumatol 27:37-43, 1988
23. Redelmeier DA, Lorig K: Assessing the clinical importance of symptomatic improvements. Arch Intern Med 153:1337-1342, 1993
24. Prevoo MLL, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM: Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48, 1995